Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1978 3
1979 3
1980 3
1981 2
1982 4
1983 5
1984 7
1985 7
1986 13
1987 8
1988 21
1989 17
1990 13
1991 14
1992 13
1993 10
1994 20
1995 20
1996 23
1997 19
1998 29
1999 25
2000 30
2001 28
2002 35
2003 40
2004 43
2005 57
2006 61
2007 78
2008 72
2009 55
2010 88
2011 89
2012 109
2013 124
2014 150
2015 165
2016 178
2017 147
2018 183
2019 203
2020 240
2021 250
2022 294
2023 254
2024 238
2025 293
2026 162

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,457 results

Results by year

Filters applied: . Clear all
Page 1
Dry eye post-cataract surgery: a systematic review and meta-analysis.
Ta H, McCann P, Xiao M, Lien T, Abbott K, Gregory DG, Qureshi R, Li T. Ta H, et al. BMC Ophthalmol. 2025 Jan 13;25(1):18. doi: 10.1186/s12886-024-03841-8. BMC Ophthalmol. 2025. PMID: 39806338 Free PMC article.
As a potential complication following cataract surgery, dry eye has the potential to impact visual outcomes, lower patient satisfaction, and be detrimental to quality of life. ...We compared postoperative dry eye outcomes with baseline including Ocular …
As a potential complication following cataract surgery, dry eye has the potential to impact visual outcomes, lower patient sat …
NOV03 for Dry Eye Disease Associated with Meibomian Gland Dysfunction: Results of the Randomized Phase 3 GOBI Study.
Tauber J, Berdy GJ, Wirta DL, Krösser S, Vittitow JL; GOBI Study Group. Tauber J, et al. Ophthalmology. 2023 May;130(5):516-524. doi: 10.1016/j.ophtha.2022.12.021. Epub 2022 Dec 24. Ophthalmology. 2023. PMID: 36574848 Free article. Clinical Trial.
PURPOSE: To evaluate the efficacy and safety of NOV03 (perfluorohexyloctane) ophthalmic drop in patients with dry eye disease (DED) associated with meibomian gland dysfunction (MGD). DESIGN: Eight-week, phase 3, multicenter, randomized, double-masked, saline- …
PURPOSE: To evaluate the efficacy and safety of NOV03 (perfluorohexyloctane) ophthalmic drop in patients with dry eye disease …
Omega-3 fatty acids supplements for dry eye - Are they effective or ineffective?
Bhargava R, Pandey K, Ranjan S, Mehta B, Malik A. Bhargava R, et al. Indian J Ophthalmol. 2023 Apr;71(4):1619-1625. doi: 10.4103/IJO.IJO_2789_22. Indian J Ophthalmol. 2023. PMID: 37026312 Free PMC article. Clinical Trial.
The primary outcome was improvement in omega-3 index (a measure of EPA and DHA ratio in RBC membrane). Secondary outcomes were improvement dry eye symptoms, Nelson grade on conjunctival impression cytology, Schirmer test values, tear film breakup time …
The primary outcome was improvement in omega-3 index (a measure of EPA and DHA ratio in RBC membrane). Secondary outcomes were improvement …
Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3).
Holland EJ, Luchs J, Karpecki PM, Nichols KK, Jackson MA, Sall K, Tauber J, Roy M, Raychaudhuri A, Shojaei A. Holland EJ, et al. Ophthalmology. 2017 Jan;124(1):53-60. doi: 10.1016/j.ophtha.2016.09.025. Epub 2016 Oct 27. Ophthalmology. 2017. PMID: 28079022 Free article. Clinical Trial.
PURPOSE: Lifitegrast is a lymphocyte function-associated antigen-1 antagonist developed to reduce inflammation in dry eye disease (DED). We report the results of OPUS-3 (NCT02284516), a phase III study evaluating the efficacy and safety of lifitegrast versus placebo …
PURPOSE: Lifitegrast is a lymphocyte function-associated antigen-1 antagonist developed to reduce inflammation in dry eye dise …
A randomized, vehicle-controlled, Phase 2b study of two concentrations of the TRPM8 receptor agonist AR-15512 in the treatment of dry eye disease (COMET-1).
Wirta DL, Senchyna M, Lewis AE, Evans DG, McLaurin EB, Ousler GW, Hollander DA. Wirta DL, et al. Ocul Surf. 2022 Oct;26:166-173. doi: 10.1016/j.jtos.2022.08.003. Epub 2022 Aug 13. Ocul Surf. 2022. PMID: 35970431 Free article. Clinical Trial.
PURPOSE: Dry eye disease (DED) symptoms can negatively impact quality of life (QoL). AR-15512, a transient receptor potential melastatin 8 (TRPM8) agonist, was evaluated as a potential therapy for DED. ...Eligibility criteria included DED signs and symptoms of presp …
PURPOSE: Dry eye disease (DED) symptoms can negatively impact quality of life (QoL). AR-15512, a transient receptor potential …
Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group.
Sall K, Stevenson OD, Mundorf TK, Reis BL. Sall K, et al. Ophthalmology. 2000 Apr;107(4):631-9. doi: 10.1016/s0161-6420(99)00176-1. Ophthalmology. 2000. PMID: 10768324 Clinical Trial.
OBJECTIVE: To compare the efficacy and safety of cyclosporin A ([CsA] 0.05% and 0.1% ophthalmic emulsions) to vehicle in patients with moderate to severe dry eye disease. DESIGN: Multicenter, randomized, double-masked, parallel-group, 6-month, vehicle-control …
OBJECTIVE: To compare the efficacy and safety of cyclosporin A ([CsA] 0.05% and 0.1% ophthalmic emulsions) to vehicle in patients with moder …
Acoltremon Ophthalmic Solution 0.003% for Signs and Symptoms of Dry Eye Disease: Results of Phase 3 Pivotal COMET-2 and COMET-3 Studies.
Pattar GR, Wirta D, Jerkins G, Paauw J, McLaurin EB, Liu A, Evans DG, Kenyon K, Cline N, Gupta PK, Meng I, Senchyna M; COMET-2 and COMET-3 Study Groups. Pattar GR, et al. Ophthalmology. 2026 May;133(5):563-574. doi: 10.1016/j.ophtha.2025.09.018. Epub 2025 Sep 30. Ophthalmology. 2026. PMID: 41038456 Free article. Clinical Trial.
PURPOSE: To evaluate the safety and efficacy of the transient receptor potential melastatin 8 agonist acoltremon on signs and symptoms of dry eye disease (DED). DESIGN: Two identical randomized, multicenter, double-masked, vehicle-controlled phase 3 studies. …
PURPOSE: To evaluate the safety and efficacy of the transient receptor potential melastatin 8 agonist acoltremon on signs and symptoms of …
The prevalence of dry eye in a very old population.
Bikbov MM, Kazakbaeva GM, Rakhimova EM, Rusakova IA, Fakhretdinova AA, Tuliakova AM, Panda-Jonas S, Gilmanshin TR, Zainullin RM, Bolshakova NI, Safiullina KR, Gizzatov AV, Ponomarev IP, Yakupova DF, Baymukhametov NE, Nikitin NA, Jonas JB. Bikbov MM, et al. Acta Ophthalmol. 2022 May;100(3):262-268. doi: 10.1111/aos.14937. Epub 2021 Jun 14. Acta Ophthalmol. 2022. PMID: 34124850 Free article.
Schirmer s test was 5 mm in 388 individuals (34.3%; 95% confidence interval (CI): 31.5, 37.1), and the mean score of subjective dry eye symptoms was 7.52 2.14 (median: 6; range: 6-18; 95%CI: 7.41, 7.63). ...The prevalence of DED diagnosis def …
Schirmer s test was 5 mm in 388 individuals (34.3%; 95% confidence interval (CI): 31.5, 37.1), and the mean score of s …
Menopause and Dry Eye Syndrome.
Lurati AR. Lurati AR. Nurs Womens Health. 2019 Feb;23(1):71-78. doi: 10.1016/j.nwh.2018.11.001. Epub 2018 Dec 27. Nurs Womens Health. 2019. PMID: 30594503
Dry eye syndrome is a common ophthalmic complaint. Women, especially menopausal women with comorbidities, are at greater risk for developing dry eye syndrome and subsequent negative effects on their overall eye health. In this article, I review …
Dry eye syndrome is a common ophthalmic complaint. Women, especially menopausal women with comorbidities, are at greater risk …
Multifactorial analysis of dry eye syndrome: insights from Schirmer's test, VDT exposure, and tear film stability.
Mereddy S, Gunnam RP, Karedla SR, Banerjee SK, Polaki S. Mereddy S, et al. Int Ophthalmol. 2025 Jun 5;45(1):225. doi: 10.1007/s10792-025-03597-0. Int Ophthalmol. 2025. PMID: 40471455
The inspection encompasses essential variables which include Schirmer's Test 1 (ST1), Tear Film Breakup Time (TBUT), ocular surface staining (OSS), tear osmolarity, blink rate, alongside symptom severity measured by the Ocular Surface Disease Index (OSDI). .. …
The inspection encompasses essential variables which include Schirmer's Test 1 (ST1), Tear Film Breakup Time (TBUT), oc …
3,457 results